Literature DB >> 18753292

Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects.

Aleksander Krag1, Flemming Bendtsen, Erling Bjerregaard Pedersen, Niels-Henrik Holstein-Rathlou, Søren Møller.   

Abstract

The vasopressin analog terlipressin is believed to cause vasoconstriction selectively by V1 receptor stimulation. However, a possible antidiuretic effect by V2 receptor stimulation has never been ruled out. Twenty-two patients with ascites, including seven with refractory ascites, were included. The subjects were studied during a 400 ml/h oral water load before and after infusion of 2 mg of terlipressin (18 patients) or placebo infusion (4 patients). Effects on the V2 receptors were assessed by evaluating aquaporin (AQP)2 excretion, free water clearance (C(H2O)), urine osmolality (Uosm), and fractional distal water excretion (DFeH2O). After terlipressin the excretion of AQP2 increased by 89% [144 ng/mmol creatinine, 95% confidence interval (CI) 73-214 ng/mmol creatinine, P = 0.001]. C(H2O) decreased 1.05 ml/min (from 0.17 to -0.89 ml/min, P = 0.001), and DFeH2O decreased 37% (19 vs. 12; 95% CI 2-11, P = 0.01). Uosm increased by 27% (93 mosmol/kgH2O, 95% CI 23-164 mosmol/kgH2O, P = 0.02). Plasma sodium decreased 1.1 mmol/l (P < 0.01). An increase in AQP2 excretion and a decrease in C(H2O) and distal water excretion after terlipressin despite water loading is a clear indication of activation of the antidiuretic system (V2 receptor effect).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753292     DOI: 10.1152/ajprenal.90407.2008

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  10 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Cortical laminar necrosis following the rapid correction of drug-induced hyponatremia.

Authors:  Xiaohui Liu; Xinya Zhao; Jiangfei Yang; Xiaojuan Han; Xiyun Ruan; Yifeng Du
Journal:  Neurol Sci       Date:  2015-05-19       Impact factor: 3.307

3.  Outpatient Terlipressin Infusion for the Treatment of Refractory Ascites.

Authors:  Paul J Gow; Zaid S Ardalan; Abhinav Vasudevan; Adam G Testro; Bei Ye; Peter W Angus
Journal:  Am J Gastroenterol       Date:  2016-07       Impact factor: 10.864

4.  Practice guidance for the use of terlipressin for liver cirrhosis-related complications.

Authors:  Xingshun Qi; Zhaohui Bai; Qiang Zhu; Gang Cheng; Yu Chen; Xiaowei Dang; Huiguo Ding; Juqiang Han; Lei Han; Yingli He; Fanpu Ji; Hongxu Jin; Bimin Li; Hongyu Li; Yiling Li; Zhiwei Li; Bang Liu; Fuquan Liu; Lei Liu; Su Lin; Dapeng Ma; Fanping Meng; Ruizhao Qi; Tianshu Ren; Lichun Shao; Shanhong Tang; Yufu Tang; Yue Teng; Chunhui Wang; Ran Wang; Yunhai Wu; Xiangbo Xu; Ling Yang; Jinqiu Yuan; Shanshan Yuan; Yida Yang; Qingchun Zhao; Wei Zhang; Yongping Yang; Xiaozhong Guo; Weifen Xie
Journal:  Therap Adv Gastroenterol       Date:  2022-05-18       Impact factor: 4.802

5.  Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

6.  Long-term continuous terlipressin infusion in cirrhotic patients with hepatorenal syndrome or refractory ascites awaiting liver transplantation is associated with an increase in plasma sodium.

Authors:  T McClure; B Chapman; P Hey; A Testro; P Gow
Journal:  United European Gastroenterol J       Date:  2019-09-19       Impact factor: 4.623

7.  Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis.

Authors:  Yeo-Jin Kang; Eun Jin Bae; Kyungo Hwang; Dae-Hong Jeon; Ha Nee Jang; Hyun Seop Cho; Se-Ho Chang; Dong Jun Park
Journal:  Springerplus       Date:  2013-10-09

8.  Baseline Renal Function Predicts Hyponatremia in Liver Cirrhosis Patients Treated with Terlipressin for Variceal Bleeding.

Authors:  Sung Eun Kim; Dong Min Jung; Ji Won Park; Yeonmi Ju; Bohyun Lee; Hyoung Su Kim; Ki Tae Suk; Myoung Kuk Jang; Sang Hoon Park; Jun Goo Kang; Jae Seung Soh; Hyun Lim; Ho Suk Kang; Sung Hoon Moon; ChulSik Kim; SeongJin Lee; Jong Hyeok Kim; Myung Seok Lee; Dong Joon Kim; Sung-Hee Ihm; ChoongKee Park
Journal:  Gastroenterol Res Pract       Date:  2017-09-17       Impact factor: 2.260

Review 9.  Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.

Authors:  Mladena Glavaš; Agata Gitlin-Domagalska; Dawid Dębowski; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

10.  Terlipressin for variceal bleeding induces large plasma sodium fluctuations in patients without cirrhosis.

Authors:  Peter Lykke Eriksen; Anne Luise Hartkopf-Mikkelsen; Peter Ott; Hendrik Vilstrup; Niels Kristian Aagaard
Journal:  United European Gastroenterol J       Date:  2018-05-28       Impact factor: 4.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.